Assessment of the hepatocyte protective effects of gypenoside and its phosphorylated derivative against DHAV-1 infection on duck embryonic hepatocytes

Table 3 A₅₇₀ values of different treatments when adding drug and virus simultaneously (n = 6)

GP Concentration (μg^.mL^− 1)	A ₅₇₀	Hepatocyte protection rate rate(%)	pGP Concentration (μg^.mL^− 1)	A ₅₇₀	Hepatocyte protection rate rate(%)
100	0.515 ± 0.004^a	108.74	25	0.509 ± 0.003^a	99.26
50	0.425 ± 0.008^b	59.56	12.5	0.487 ± 0.005^a	82.96
25	0.374 ± 0.008^c	31.69	6.25	0.421 ± 0.007^b	34.07
12.5	0.353 ± 0.008^d	20.22	3.125	0.422 ± 0.010^b	34.81
6.25	0.336 ± 0.008^de	10.93	1.563	0.401 ± 0.007^bc	19.26
3.125	0.322 ± 0.007^e	3.28	0.781	0.396 ± 0.007^bc	15.56
0(VC)	0.316 ± 0.006^e		0(VC)	0.375 ± 0.005^c
0(CC)	0.499 ± 0.005^a		0(CC)	0.510 ± 0.005^a

^a-eData in same column without same superscript (a–e) differ significantly(P < 0.05)
GP Gypenoside, pGP phosphorylated gypenoside, VC virus control, CC cell control